TOTAL PREDICTED MHC-I EPITOPE LOAD IS INVERSELY ASSOCIATED WITH POPULATION MORTALITY FROM SARS-COV-2

Eric A. Wilson School of Molecular Sciences Arizona State University **Gabrielle Hirneise** School of Life Sciences Arizona State University

Abhishek Singharoy* School of Molecular Sciences Arizona State University

Karen S. Anderson* Biodesign Institute Arizona State University

December 15, 2020

ABSTRACT

Polymorphisms in MHC-I protein sequences across human populations significantly impacts viral peptide binding capacity and thus alters T cell immunity to infection. Consequently, allelic variants of the MHC-I protein have been found to be associated with patient outcome to various viral infections, including SARS-CoV. In the present study, we assess the relationship between observed SARS-CoV-2 population mortality and the predicted viral binding capacities of 52 common MHC-I alleles. Potential SARS-CoV-2 MHC-I peptides were identified using a consensus MHC-I binding and presentation prediction algorithm, called EnsembleMHC. Starting with nearly 3.5 million candidates, we resolved a few hundred highly probable MHC-I peptides. By weighing individual MHC allele-specific SARS-CoV-2 binding capacity with population frequency in 23 countries, we discover a strong inverse correlation between the predicted population SARS-CoV-2 peptide binding capacity and observed mortality rate. Our computations reveal that peptides derived from the structural proteins of the virus produces a stronger association with observed mortality rate, highlighting the importance of S, N, M, E proteins in driving productive immune responses. The correlation between epitope binding capacity and population mortality risk remains robust across a range of socioeconomic and epidemiological factors. A combination of binding capacity, number of deaths due to COPD complications, gender demographics, and the proportions of the population that were over the age of 65 and overweight offered the strongest determinant of at-risk populations. These results bring to light how molecular changes in the MHC-I proteins may affect population-level outcomes of viral infection.

Keywords SARS-CoV-2 · EnsembleMHC · MHC-I · risk-model · binding predictions · consensus models · population dynamics

^{*}corresponding author

A PREPRINT - DECEMBER 15, 2020

o Introduction

1 In December 2019, the novel coronavirus, SARS-CoV-2 was

identified from a cluster of cases of pneumonia in Wuhan,
China^{1,2}. With over 73.1 million cases and over 1.6 million
deaths, the viral spread has been declared a global pandemic by
the World Health Organization³. Due to its high rate of transmission and unpredictable severity, there is an immediate need
for information surrounding the adaptive immune response

8 towards SARS-CoV-2.

A robust T cell response is integral for the clearance of 9 coronaviruses, and generation of lasting immunity⁴. The poten-10 tial role of T cells for coronavirus clearance has been supported 11 by the identification of immunogenic CD8⁺ T cell epitopes in 12 the S (Spike), N (Nucleocapsid), M (Membrane), and E (En-13 velope) proteins⁵. Additionally, SARS-CoV specific CD8⁺ T 14 cells have been shown to provide long lasting immunity with 15 memory CD8⁺ T cells being detected up to 17 years post infec-16 tion^{4,6,7}. The specifics of the T cell response to SARS-CoV-2 17 is still evolving. However, a recent screening of SARS-CoV-18 2 peptides revealed a majority of the CD8⁺ T cell immune 19 response is targeted towards viral structural proteins (N, M, 20 $(S)^{8}$. 21

A successful CD8⁺ T cell response is contingent on the 22 efficient presentation of viral protein fragments by Major Histo-23 compatibility Complex I (MHC-I) proteins. MHC-I molecules 24 bind and present peptides derived from endogenous proteins 25 on the cell surface for CD8⁺ T cell interrogation. The MHC-I 26 protein is highly polymorphic, with amino acid substitutions 27 within the peptide binding groove drastically altering the com-28 position of presented peptides. Consequently, the influence 29 of MHC genotype to shape patient outcome has been well 30 studied in the context of viral infections⁹. For coronaviruses, 31 there have been several studies of MHC association with dis-32 ease susceptibility. A study of a Taiwanese and Hong Kong 33 cohort of patients with SARS-CoV found that the MHC-I alle-34 les HLA-B*07:03 and HLA-B*46:01 were linked to increased 35 susceptibility while HLA-Cw*15:02 was linked to increased 36 resistance^{10–12}. However, some of the reported associations 37 did not remain after statistical correction, and it is still un-38 clear if MHC-outcome associations reported for SARS-CoV 39 are applicable to SARS-CoV-2^{13,14}. Recently, a comprehensive 40 prediction of SARS-CoV-2 MHC-I peptides indicated a relative 41 depletion of high affinity binding peptides for HLA-B*46:01, 42 hinting at a similar association profile in SARS-CoV-2¹⁵. More 43 importantly, it remains elusive if such a depletion of putative 44 high affinity peptides will impact patient outcome to SARS-45 CoV-2 infections. 46

The lack of large scale genomic data linking individual MHC genotype and outcome from SARS-CoV-2 infections

precludes a similar analysis as performed for SARS-CoV¹⁰⁻¹². 49 Therefore, we endeavored to assess the relationship between 50 the predicted SARS-CoV-2 binding capacity of a population 51 and the observed SARS-CoV-2 mortality rate. However, cur-52 rent MHC-I prediction algorithms have been characterized by 53 a high false positive rate particularly when predicting peptides 54 that are naturally presented^{16,17}. To mitigate false positives and 55 identify the highest confidence SARS-CoV-2 MHC-I peptides, 56 we developed a consensus prediction algorithm, coined En-57 sembleMHC, and predicted MHC-I peptides for a panel of 52 58 common MHC-I alleles¹⁸. This prediction workflow integrates 59 seven different algorithms that have been parameterized on 60 high-quality mass spectrometry data and provides a confidence 61 level for each identified peptide^{17,19–24}. The distribution of the 62 number of high-confidence peptides assigned to each allele was 63 used to assess a country-specific SARS-CoV-2 binding capacity, 64 called the EnsembleMHC population score, for 23 countries 65 (for selection criteria, please refer to the methods). This score 66 was derived by weighing the individual binding capacities of 67 the 52 MHC-I alleles by their endemic frequencies. We observe 68 a strong inverse correlation between the EnsembleMHC popu-69 lation score and observed population SARS-CoV-2 mortality. 70 Furthermore, the correlation is shown to become stronger when 71 considering EnsembleMHC population scores based solely on 72 SARS-CoV-2 structural proteins, underlining their potential im-73 portance in driving a robust immune response. Based on their 74 predicted binding affinity, expression, and sequence conserva-75 tion in viral isolates, we identified 108 peptides derived from 76 SARS-CoV-2 structural proteins that are high-value targets for 77 CD8⁺ T cell vaccine development. 78

Results

EnsembleMHC workflow offers more precise MHC-I pre-80 sentation predictions than individual algorithms. The ac-81 curate assessment of differences in SARS-CoV-2 binding ca-82 pacities across MHC-I allelic variants requires the isolation 83 of MHC-I peptides with a high probability of being presented. 84 EnsembleMHC provides the requisite precision through the use 85 of allele and algorithm-specific score thresholds and peptide 86 confidence assignment. 87

79

MHC-I alleles substantially vary in both peptide bind-88 ing repertoire size and median binding affinity²⁵. The Ensem-89 bleMHC workflow addresses this inter-allele variation by iden-90 tifying peptides based on MHC allele and algorithm-specific 91 binding affinity thresholds. These thresholds were set by bench-92 marking each of the seven component algorithms against 52 93 single MHC allele peptide data sets¹⁷. Each data set consists of 94 mass spectrometry-confirmed MHC-I peptides that have been 95 naturally presented by a model cell line expressing one of the 52 96

A PREPRINT - DECEMBER 15, 2020



Figure 1: **Application of the EnsembleMHC prediction algorithm.** The EnsembleMHC prediction algorithm was used to recover MHC-I peptides from 10 tumor sample data sets. **A**, The average precision and recall for EnsembleMHC and each component algorithm was calculated across all 10 tumor samples. Peptide identification by each algorithm was based on commonly used restrictive (strong) or permissive (strong and weak) binding affinity thresholds (**inset table**). **B**, The F1 score of each algorithm was calculated for all tumor samples. Each algorithm is grouped into 1 of 4 categories: binding affinity represented by percentile score (blue), binding affinity represented by predicted peptide IC50 value (green), MHC-I presentation prediction (orange), and EnsembleMHC (brown). The heatmap colors indicate the value of the observed F1 score (color bar) for a given algorithm (y-axis) on a particular data set (x-axis). Warmer colors indicate higher F1 scores, and cooler colors indicate lower F1 scores. The average F1 score for each algorithm across all samples is shown in the marginal bar plot. **C**, The schematic for the application of the EnsembleMHC predication algorithm to identify SARS-CoV-2 MHC-I peptides.

select MHC-I alleles. These experimentally validated peptides, 97 denoted target peptides, were supplemented with a 100-fold 98 excess of decoy peptides. Decoys were generated by randomly 99 sampling peptides that were not detected by mass spectrometry, 100 but were derived from the same protein sources as a detected 101 target peptide. Algorithm and allele-specific binding affinity 102 thresholds were then identified through the independent appli-103 cation of each component algorithm to all MHC allele data sets. 104

For every data set and algorithm combination, the target and 105 decoy peptides were ranked by predicted binding affinity to 106 the MHC allele defined by that data set. Then, an algorithm-107 specific binding affinity threshold was set to the minimum score 108 needed to isolated the highest affinity peptides commensurate 109 to 50% of the observed allele repertoire size (methods, SI 110 A.1). The observed allele repertoire size was defined as the 111 total number of target peptides within a given single MHC al-112

lele data set. Therefore, if a data set had 1000 target peptides,
the top 500 highest affinity peptides would be selected, and
the algorithm-specific threshold would be set to the predicted
binding affinity of the 500th peptide. This parameterization
method resulted in the generation of a customized set of allele
and algorithm-specific binding affinity thresholds in which an
expected quantity of peptides can be recovered.

Consensus MHC-I prediction typically require a method 120 for combining outputs from each individual component algo-121 rithm into a composite score. This composite score is then 122 used for peptide selection. EnsembleMHC identifies high-123 confidence peptides based on filtering by a quantity called 124 $peptide^{FD\vec{R}}$ (methods Eq. 1). During the identification of 125 allele and algorithm-specific binding affinity thresholds, the 126 empirical false detection rate (FDR) of each algorithm was cal-127 culated. This calculation was based on the proportion of target 128 to decoy peptides isolated by the algorithm specific binding affinity threshold. A $peptide^{FDR}$ is then assigned to each indi-129 130 vidual peptide by taking the product of the empirical FDRs of 131 each algorithm that identified that peptide for the same MHC-I 132 allele. Analysis of the parameterization process revealed that 133 134 the overall performance of each included algorithms was comparable, and there was diversity in individual peptide calls by 135 each algorithm, supporting an integrated approach to peptide 136 confidence assessment (SI A.2). Peptide identification by En-137 sembleMHC was performed by selecting all peptides with a $peptide^{FDR}$ of less than or equal to $5\%^{26}$. 138 139

The efficacy of $peptide^{FDR}$ as a filtering metric was de-140 termined through the prediction of naturally presented MHC-I 141 peptides derived from ten tumor samples¹⁷ (Figure 1). Similar 142 to the single MHC allele data sets, each tumor sample data set 143 consisted of mass spectrometry-detected target peptides and a 144 100-fold excess of decoy peptides. The relative performance of 145 EnsembleMHC was assessed via comparison with individual 146 component algorithms. Peptide identification by each algo-147 rithm was based on a restrictive or permissive binding affinity 148 thresholds (Figure 1A (inset table)). For the component algo-149 rithms, the permissive and restrictive thresholds correspond to 150 commonly used binding affinity cutoffs for the identification of 151 weak and strong binders, respectively²⁷. The performance of 152 each algorithm on the ten data sets was evaluated through the 153 calculation of the empirical precision, recall, and F1 score. 154

155 The average precision and recall of each algorithm across 156 all tumor samples demonstrated an inverse relationship (Figure **1A).** In general, restrictive binding affinity thresholds produced 157 higher precision at the cost of poorer recall. When comparing 158 the precision of each algorithm at restrictive thresholds, En-159 sembleMHC demonstrated a 3.4-fold improvement over the 160 median precision of individual component algorithms. Ensem-161 bleMHC also produced the highest F1 score with an average 162 163 of 0.51 followed by mhcflurry-presentation with an F1 score

of 0.45, both of which are 1.5-2 fold higher than the rest of 164 the algorithms (Figure 1B). result was shown to be robust 165 across a range of $peptide^{FDR}$ cutoff thresholds (SI A.3) and 166 alternative performance metrics (SI A.4). Furthermore, Ensem-167 bleMHC demonstrated the ability to more efficiently prioritize 168 peptides with experimentally established immunogenicity from 169 the Hepatitis-C genome polyprotein, the Dengue virus genome 170 polyprotein, and the HIV-1 POL-GAG protein (SI A.5). Taken 171 together, these results demonstrate the enhanced precision of 172 EnsembleMHC over individual component algorithms when 173 using common binding affinity thresholds. 174

In summary, the EnsembleMHC workflow offers two 175 desirable features. First, it determines allele-specific binding 176 affinity thresholds for each algorithm at which a known quantity 177 of peptides are expected to be successfully presented on the cell 178 surface. Second, it assigns a confidence level to each peptide 179 call made by each algorithm. Together, these traits enhance the 180 ability to identify MHC-I peptides with a high probability of 181 successful cell surface presentation. 182

EnsembleMHC was used to identify MHC-I peptides 183 for the SARS-CoV-2 virus (Figure 1C). The resulting identi-184 fication of high-confidence SARS-CoV-2 peptides allows for 185 the characterization of alleles that are enriched or depleted 186 for predicted MHC-I peptides. The resulting distribution of 187 allele-specific SARS-CoV-2 binding capacities will then be 188 weighed by the normalized frequencies of the 52 alleles (SI A.6, 189 Methods Eq. 5-6) in 23 countries to determine the population-190 specific SARS-CoV-2 binding capacity or EnsembleMHC pop-191 ulation score (Methods Eq. 7). The potential impact of varying 192 population SARS-CoV-2 binding capacities on disease outcome 193 can then be assessed by correlating population SARS-CoV-2 194 mortality rates with EnsembleMHC population scores. Below, 195 we use EnsembleMHC population scores to stratify countries 196 based on their mortality risks. 197

The MHC-I peptide-allele distribution for SARS-CoV-2 198 structural proteins is especially disproportionate. MHC-I 199 peptides derived from the SARS-CoV-2 proteome were pre-200 dicted and prioritized using EnsembleMHC. A total of 67,207 201 potential 8-14mer viral peptides were evaluated for each of the 202 considered MHC-I alleles. After filtering the pool of candi-203 date peptides at the 5% $peptide^{FDR}$ threshold, the number of 204 potential peptides was reduced from 3.49 Million to 971 (658 205 unique peptides) (SI A.7, SI table B.1). Illustrated in Figure 206 **2A**, the viral peptide-MHC allele (or peptide-allele) distribu-207 tion for high-confidence SARS-CoV-2 peptides was determined 208 by assigning the identified peptides to their predicted MHC-I 209 alleles. There was a median of 16 peptides per allele with a 210 maximum of 47 peptides (HLA-A*24:02), a minimum of 3 211 peptides (HLA-A*02:05), and an interquartile range (IQR) of 212 16 peptides. Quality assurance of the predicted peptides was 213 performed by computing the peptide length frequencies and 214

A PREPRINT - DECEMBER 15, 2020



Figure 2: **Prediction of SARS-CoV-2 peptides across 52 common MHC-I alleles. A-B**, The EnsembleMHC workflow was used to predict MHC-I peptides for 52 alleles from the entire SARS-CoV-2 proteome or specifically SARS-CoV-2 structural proteins (envelope, spike, nucleocapsid, and membrane). **C**, The peptide fractions for both protein sets were calculated by dividing the number of peptides assigned to a given allele by the total number of identified peptides for that protein set. Each line indicates the change in peptide fraction observed by a given allele when comparing the viral peptide-MHC allele distribution for the full SARS-CoV-2 proteome or structural proteins. Alleles showing a change of greater than the median peptide fraction, $\tilde{X} = 0.015$, are highlighted in color. For the performance of EnsmebleMHC at a range of different *peptide^{FDR}* cutoff thresholds, refer to **SI A.3**

binding motifs. The predicted peptides were found to adhere to 215 expected MHC-I peptide lengths²⁸ with 78% of the peptides be-216 ing 9 amino acids in length, 13% being 10 amino acids in length, 217 and 8% of peptides accounting for the remaining lengths (SI 218 A.8). Similarly, logo plots generated from predicted peptides 219 were found to closely reflect reference peptide binding motifs 220 for considered alleles²⁹(SI A.9). Overall, the EnsembleMHC 221 222 prediction platform demonstrated the ability to isolate a short

list of potential peptides which adhere to expected MHC-I peptide characteristics. 224

The high expression, relative conservation, and reduced search space of SARS-CoV-2 structural proteins (S, E, M, and N) makes MHC-I binding peptides derived from these proteins high-value targets for CD8⁺ T cell-based vaccine development. **Figure 2B** describes the peptide-allele distribution for predicted MHC-I peptides originating from the four structural proteins. This analysis markedly reduces the number of con-

A PREPRINT - DECEMBER 15, 2020

sidered peptides from 658 to 108 (SI table B.1). The median 232 number of predicted SARS-CoV-2 structural peptides assigned 233 to each MHC-I allele was found to be 2 with a maximum of 234 12 peptides (HLA-B*53:01), a minimum of 0 (HLA-B*15:02, 235 B*35:03,B*38:01,C*03:03,C*15:02), and a IQR of 3 peptides. 236 Analysis of the molecular source of the identified SARS-CoV-2 237 238 structural protein peptides revealed that they originate from enriched regions that are highly conserved (SI A.10-A.11). This 239 indicates that such peptides would be good candidates for tar-240 geted therapies as they are unlikely to be disrupted by mutation, 241 and several peptides can be targeted using minimal stretches 242 of the source protein. Altogether, consideration of MHC-I 243 peptides derived only from SARS-CoV-2 structural proteins 244 reduces the number of potential peptides to a condensed set of 245 high-value targets that is amenable to experimental validation. 246

Both the peptide-allele distributions, namely the ones de-247 rived from the full SARS-CoV-2 proteome and those from the 248 structural proteins, were found to significantly deviate from an 249 even distribution of predicted peptides as apparent in figure 250 2AB and reflected in the Kolmogorov-Smirnov test p-values 251 (SI A.12, full proteome = 5.673e-07 and structural proteins 252 253 = 1.45e-02). These results support a potential allele-specific hierarchy for SARS-CoV-2 peptide presentation. 254

To determine if the MHC-I binding capacity hierarchy 255 was consistent between the full SARS-CoV-2 proteome and 256 SARS-CoV-2 structural proteins, the relative changes in the ob-257 served peptide fraction (number of peptides assigned to an allele 258 / total number of peptides) between the two protein sets was vi-259 sualized (Figure 2C). Six alleles demonstrated changes greater 260 than the median peptide fraction (X = 0.015) when comparing 261 the two protein sets. The greatest decrease in peptide fraction 262 263 was observed for A*25:01 (1.52 times the median peptide fraction), and the greatest increase was seen with B*53:01 (2.38 264 times the median peptide fraction). Furthermore, the resulting 265 SARS-CoV-2 structural protein peptide-allele distribution was 266 found to be more variable than the distribution derived from the 267 full SARS-CoV-2 proteome with a quartile coefficient of disper-268 sion of 0.6 compared to 0.44, respectively. This indicates that 269 peptides derived from SARS-CoV-2 structural proteins experi-270 ence larger relative inter-allele binding capacity discrepancies 271 than peptides derived from the the full SARS-CoV-2 proteome. 272 Together, these results indicate a potential MHC-I binding ca-273 pacity hierarchy that is more pronounced for SARS-CoV-2 274 structural proteins. 275

Total population epitope load inversely correlates with reported death rates from SARS-CoV-2. The documented importance of MHC-I peptides derived from SARS-CoV-2 structural proteins⁸, coupled with the observed MHC allele binding capacity hierarchy and the high immunogenicity rate of
SARS-CoV-2 structural protein MHC-I peptides identified by
EnsembleMHC (95% peptides tested *in vitro*, SI A.13), prompts

a potential relationship between MHC-I genotype and infection outcome. However, due to the absence of MHC genotype data for SARS-CoV-2 patients, we assessed this relationship at the population-level by correlating predicted country-specific SARS-CoV-2 binding capacity (or EnsembleMHC population score) with observed SARS-CoV-2 mortality. 288

EnsembleMHC population scores (EMP) were deter-289 mined for 23 countries (SI B.2) by weighing the individual 290 binding capacities of 52 common MHC-I alleles by their nor-291 malized endemic expression¹⁸ (methods, SI A.6). This results 292 in every country being assigned two separate EMP scores, one 293 calculated with respect to the 108 unique SARS-CoV-2 struc-294 tural protein peptides (structural protein EMP) and the other 295 with respect to the 658 unique peptides derived from the full 296 SARS-CoV-2 proteome (full proteome EMP). The EMP score 297 corresponds to the average predicted SARS-CoV-2 binding ca-298 pacity of a population. Therefore, individuals in a country with 299 a high EMP score would be expected, on average, to present 300 more SARS-CoV-2 peptides to CD8⁺ T cells than individuals 301 from a country with a low EMP score. The resulting EMP 302 scores were then correlated with observed SARS-CoV-2 mor-303 tality (deaths per million) as a function of time. Temporal 304 variance in community spread within the cohort of countries 305 was corrected by truncating the SARS-CoV-2 mortality data 306 set for each country to start after a certain minimum death 307 threshold was met. For example, if the minimum death thresh-308 old was 50, then day 0 would be when each country reported 309 at least 50 deaths. The number of countries included in each 310 correlation decreases as the number of days increases due to 311 discrepancies in the length of time that each country met a given 312 minimum death threshold (SI table B.3). Therefore, the cor-313 relation between EMP score and SARS-CoV-2 mortality was 314 only estimated at time points where there were at least eight 315 countries. The eight country threshold was chosen because it is 316 the minimum sample size needed to maintain sufficient power 317 when detecting large effect sizes ($\rho > 0.85$). The strength of the 318 relationship between EMP score and SARS-CoV-2 mortality 319 was determined using Spearman's rank-order correlation (for 320 details concerning the choice of statistical tests, please refer 321 to the methods section). Accordingly, both EMP scores and 322 SARS-CoV-2 mortality data were converted into ascending 323 ranks with the lowest rank indicating the minimum value and 324 the highest rank indicating the maximum value. For instance, a 325 country with an EMP score rank of 1 and death per million rank 326 of 23 would have the lowest predicted SARS-CoV-2 binding 327 capacity and the highest level of SARS-CoV-2-related mortal-328 ity. Using the described paradigm, the structural protein EMP 329 score and the full proteome EMP score were correlated with 330 SARS-CoV-2-related deaths per million for 23 countries. 331

Total predicted population SARS-CoV-2 binding capacity 332 exhibited a strong inverse correlation with observed deaths per 333

A PREPRINT - DECEMBER 15, 2020



Figure 3: Predicted total epitope load within a population inversely correlates with mortality. A, SARS-CoV-2 structural protein-based EnsembleMHC population scores were assigned to 23 countries (SI B.2), and correlated with observed mortality rate (deaths per million). The correlation coefficient is presented as a function of time. Individual country mortality rate data were aligned by truncating each data set to start after a minimum threshold of deaths was observed in a given country (line color). The Spearman's rank correlation coefficient between structural protein EMP score and SARS-CoV-2 mortality rate was calculated at every day following day 0 for each of the minimum death thresholds. Due to the differing lengths of time series analysis at each minimum death threshold, the number of days were normalized to improve visualization. Thus, normalized day 0 represents the day when qualifying countries recorded at least the number of deaths indicated by the minimum death threshold, and normalized day 1 represents the final time point at which a correlation was measured. (For mapping between real and normalized days, see SI B.2). Correlations that were shown to be statistically significant (p-value < 0.05) are indicated by a red point. B, The correlations between the structural protein EnsembleMHC population score (y-axis) and deaths per million (x-axis) were shown for countries meeting the 50 minimum deaths threshold at days 1, 6, 12, 17, and 22. Correlation coefficients and p-values were assigned using Spearman's rank correlation and the shaded region signifies the 95% confidence interval. Due to Spearman's rank correlation only considering data rank, Deaths per million and EnsembleMHC population score were converted to ascending rank values (low rank = low values, high rank = high values) to improve visualization of the measured relationship. Red points indicate a country that has an EnsembleMHC population rank less than the median EnsembleMHC population rank of all countries at that day, and blue points indicate a country with an EnsembleMHC population rank greater than the median EnsembleMHC population rank. C. The countries at each day were partitioned into a upper or lower half based on the median observed EnsembleMHC population rank. Therefore, countries with an EnsembleMHC population rank greater than the median group EnsembleMHC population score were assigned to the upper half (red), and the remaining countries were assigned to the lower half (blue). p-values were determined by Mann-Whitney U test. The presented box plots are in the style of Tukey (box defined by 25%, 50%, 75% quantiles, and whiskers \pm 1.5 \times IQR). The increasing gap between the red and the blue box plots indicates a greater discrepancy in the number of deaths per million between the two groups. The p values in all figures were corrected using the Benjamini-Hochberg procedure relative to the number of tests performed for each death threshold

million. This relationship was found to be true for correlations 334 based on the structural protein EMP (Figure 3A) and full pro-335 teome EMP (SI A.14) scores with a mean effect size of -0.66 336 and -0.60, respectively. Significance testing of the correlations 337 produced by both EMP scores revealed that the majority of 338 reported correlations are statistically significant with 63% at-339 340 taining a p-value of ≤ 0.05 . Correlations based on the structural protein EMP score demonstrated a 24% higher proportion of 341 statistically significant correlations compared to the full pro-342 teome EMP score (74% vs 51%). Furthermore, correlations 343 for EMP scores based on structural proteins produced narrower 344 95% confidence intervals (SI A.15-A.16, SI table B.3). Due 345 to relatively low statistical power of the obtained correlations 346 (SI A.17), the positive predictive value for each correlation 347 (methods, Eq. 8) was calculated. The resulting proportions 348 of correlations with a positive predictive value of $\geq 95\%$ were 349 similar to the observed significant p-value proportions with 350 62% of all measured correlations, 72% of structural protein 351 EMP score correlations, and 52% full proteome EMP score 352 correlations (SI A.14). The similar proportions of significant 353 p-values and PPVs supports that an overall true association is 354 being captured. Furthermore, analysis of similar sized peptide 355 sets sampled from the full SARS-CoV-2 proteome revealed that 356 the observed distinction between the correlations produced by 357 the two protein groups are unlikely to be due to differences in 358 peptide set sizes (SI A.18) 359

Finally, the reported correlations did not remain after ran-360 domizing the allele assignment of predicted peptides prior to 361 $peptide^{\bar{F}DR}$ filtering (SI A.19), through the use of any indi-362 vidual algorithm (SI A.20). This indicates that the observed 363 relationship is contingent on the high-confidence peptide-allele 364 distribution produced by the EnsembleMHC prediction algo-365 rithm. Altogether, these data demonstrate that the MHC-I allele 366 hierarchy characterized by EnsembleMHC is inversely asso-367 ciated with SARS-CoV-2 population mortality, and that the 368 relationship becomes stronger when considering only the pre-369 sentation of SARS-CoV-2 structural proteins. 370

The ability to use structural protein EMP score to identify 371 high and low risk populations was assessed using the median 372 minimum death threshold (50 deaths) at evenly spaced time 373 points (Figure 3A, squares). All correlations, with the excep-374 tion of day 1, were found to be significant with an average 375 effect size of -0.71 (Figure 3B). Next, the countries at each 376 day were partitioned into a high or low group based based on 377 whether their assigned EMP score was higher or lower than 378 the median observed EMP score (Figure 3C). The resulting 379 grouping demonstrated a statistically significant difference in 380 the median deaths per million between countries with low struc-381 tural protein EMP score and countries with high structural 382 383 protein EMP scores. Additionally, it was observed that deaths 384 per million increased much more rapidly in countries with low structural protein EMP scores. Taken together, these results indicate that structural protein EMP score may be useful for assessing population risk from SARS-CoV-2 infections.

In summary, we make several important observations. 388 First, there is a strong inverse correlation between predicted 389 population SARS-CoV-2 binding capacity and observed deaths 390 per million. This finding suggests that outcome to SARS-CoV-391 2 may be tied to total epitope load. Second, the correlation 392 between predicted epitope load and population mortality is 393 stronger for SARS-CoV-2 structural MHC-I peptides. This 394 suggests that CD8⁺ T cell-mediated immune response maybe 395 primarily driven by recognition of epitopes derived from these 396 proteins, a finding supported by recent T cell epitope mapping 397 of SARS-CoV-2⁸. Finally, the EnsembleMHC population score 398 can separate countries within the considered cohort into high 399 or low risk populations. 400

Structural protein EMP score correlates better with population outcome than identified individual risk factors.

Recent large scale patient studies have identified several socioeconomic and health-related factors associated with increased risk of death from SARS-CoV-2 infections^{31,32}. To delineate the relative importance of the structural protein EMP score as a SARS-CoV-2 severity descriptor, 12 additional risk factors were assessed for their ability to model population level SARS-CoV-2 outcome in 21 countries (**SI B.4**).

Overall, the structural protein EMP scores produced a 410 significantly stronger association with population SARS-CoV-2 411 mortality compared to other 12 descriptors (Figure 4A). While 412 various effect size trends were observed, all additional covari-413 ates failed to produce statistically significant correlations. To 414 determine if the modeling of SARS-CoV-2 mortality rate could 415 be improved by the combination of single socioeconomic or 416 health-related risk factors with structural protein EMP scores, 417 a set of linear models consisting of either a single risk factor 418 (single feature model) or that factor combined with structural 419 protein EMP scores (combination model) were generated for 420 every time point across each minimum death threshold (meth-421 ods). Following model generation, the adjusted coefficient of 422 determination (R^2) and significance level of each individual 423 model was extracted and aggregated by dependent variable 424 (SI A.21). Single feature models were characterized by low 425 R^2 ($\tilde{x} = -0.0262$) while combination models showed signifi-426 cant improvement ($\tilde{x} = .496$). Similarly, combination models 427 demonstrated a substantially higher proportion of statistical 428 significance (SI A.21B). To determine the set of features that 429 produce the best fitting model, all possible combinations of 430 explanatory factors (risk factors and structural protein EMP 431 score) were tested. Subsequently, the top ten performing mod-432 els, ranked by adjusted R^2 value, were selected for analysis 433 (Figure 4B). The identified models were found to be largely sig-434

A PREPRINT - DECEMBER 15, 2020



Figure 4: Analysis of other SARS-CoV-2 covariates with observed SARS-CoV-2 population mortality and development of an integrative model. A, 12 covariates associated with SARS-CoV-2 mortality on the individual patent level were assessed for correlation with population level mortality (SI table B.4). The correlation of each country-level covariate was determined at each time point after a minimum death threshold was met (line color). The x-axis represents the number of days (normalized) following when a minimum death threshold was met, and the y-axis indicates the observed effect size for that covariate at a given time point. Correlations achieving statistical significance are colored with a red dot. B, All possible combinations of covariates were used to fit a linear model. The top 10 models, ranked by median adjusted R^2 (red bars), were identified (B). The proportion of regressions performed by that model that were found to be statistically significant (F-test 0.05) are represented by the blue bars.

nificant (average proportion of significant regressions = 72%) and produce strong fits to the data (average $R^2 = 0.7$).

Analysis of the dependent variables included in the top
performing models revealed that all models included structural
protein EMP scores followed by deaths per million due to complications from COPD (90% of models). The median model
size included 3 features with a maximum of 5 features and a
minimum of 2 features. The model producing the best fit (me-

dian $R^2 = 0.791$) consisted of structural protein EMP scores, 443 gender demographics, number of deaths due to COPD compli-444 cations, the proportion of the population over the age of 65, and 445 proportion of the population that is overweight (Figure 4B). 446 All together, these results further indicate the robustness of the 447 structural protein EMP score as a population level risk descrip-448 tor and identifies a potential candidate model for predicting 449 pandemic severity. 450

A PREPRINT - DECEMBER 15, 2020

451 Discussion

452 In the present study, we uncover evidence supporting an associ-453 ation between population SARS-CoV-2 infection outcome and MHC-I genotype. In line with related work highlighting the 454 relationship between total epitope load with HIV viral control³³. 455 we arrive at a working model that MHC-I alleles presenting 456 more unique SARS-CoV-2 epitopes will be associated with 457 lower mortality due to a higher number of potential T cell 458 targets. The SARS-CoV-2 binding capacities of 52 common 459 MHC-I alleles were assessed using the EnsembleMHC predic-460 tion platform. These predictions identified 971 high-confidence 461 MHC-I peptides out of a candidate pool of nearly 3.5 million. In 462 agreement with other *in silico* studies^{15,34}, the assignment of the 463 predicted peptides to their respective MHC-I alleles revealed an 464 uneven distribution in the number of peptides attributed to each 465 allele. We discovered that the MHC-I peptide-allele distribution 466 originating from the full SARS-CoV-2 proteome undergoes a 467 notable rearrangement when considering only peptides derived 468 from viral structural proteins. The structural protein-specific 469 peptide-allele distribution produced a distinct hierarchy of al-470 lele binding capacities. This finding has important clinical 471 implications as a majority of SARS-CoV-2 specific CD8⁺ T 472 cell response is directed towards SARS-CoV-2 structural pro-473 teins⁸. Therefore, patients who express MHC-I alleles enriched 474 475 with a large potential repertoire of SARS-CoV-2 structural proteins peptides may benefit from a broader CD8⁺ T cell immune 476 response. 477

The variations in SARS-CoV-2 peptide-allele distribu-478 tions were analyzed at epidemiological scale to track its impact 479 on country-specific mortality. Each of the 23 countries were 480 assigned a population SARS-CoV-2 binding capacity (or En-481 sembleMHC population score) based on the individual binding 482 capacities of the selected 52 MHC-I alleles weighted by their 483 endemic population frequencies. This hierarchization revealed 484 a strong inverse correlation between EnsembleMHC population 485 score and observed population mortality, indicating that popula-486 tions enriched with high SARS-CoV-2 binding capacity MHC-I 487 alleles may be better protected. The correlation was shown to 488 be stronger when calculating the EnsembleMHC population 489 490 scores with respect to only structural proteins, reinforcing their relevance to viral immunity. Finally, The molecular origin of 491 the 108 predicted peptides specific to SARS-CoV-2 structural 492 proteins revealed that they are derived from enriched regions 493 with a minimal predicted impact from amino acid sequence 494 polymorphisms. 495

The utility of structural protein EnsembleMHC population scores was further supported by a multivariate analysis of additional SARS-CoV-2 risk factors. These results emphasized the relative robustness of structural protein EMP scores as a population risk assessment tool. Furthermore, a linear model based on the combination of structural protein EMP scores and select population-level risk factors was identified a potential candidate for a predictive model for pandemic severity. As such, the incorporation of the structural protein EMP score in more sophisticated models will likely improve epidemiological modeling of pandemic severity.

In order to achieve the highest level of accuracy in MHC-I 507 predictions, the most up-to-date versions of each component 508 algorithm were used. However, this meant that several of the al-509 gorithms (MHCflurry, netMHCpan-EL-4.0 and MixMHCpred) 510 were benchmarked against subsets of mass spectrometry data 511 that were used in the original training of these MHC-I predic-512 tion models. While this could result in an unfair weight applied 513 to these algorithms in $peptide^{FDR}$ calculation, the individual 514 FDRs of MHCflurry, netMHCpan-EL-4.0 and MixMHCpred 515 were comparable to algorithms without this advantage (SI A.2). 516 Furthermore, the peptide selection of SARS-CoV-2 peptides 517 was shown to be highly cooperative within EnsembleMHC (SI 518 A.7), and individual algorithms failed to replicate the strong 519 observed correlations between population binding capacity and 520 observed SARS-CoV-2 mortality (SI A.20). 521

In the future, the presented model could be applied to pre-522 dict individual T cell capacity to mount a robust SARS-CoV-2 523 immune response. Evolutionary divergence of patient MHC-I 524 genotypes have shown to be predictive of response to immune 525 checkpoint therapy in cancer and HIV^{35,36}. However, confirma-526 tion will require large data sets associating individual patient 527 MHC-I genotype and outcome. Additionally, future use of En-528 sembleMHC to design personalized T cell vaccines will require 529 broad experimental validation of high scoring peptides, since 530 EnsembleMHC predicts MHC-I peptides with a high proba-531 bility of antigen presentation as opposed to directly predicting 532 peptide immunogenicity. While previous work has determined 533 that a majority of successfully presented viral MHC-I peptides 534 are immunogenic³⁷, there is an expectation that some presented 535 SARS-CoV-2 MHC-I peptides will fail to produce an immune 536 response. 537

The current work assessed the relative importance of the 538 structural protein EMP score with respect to other population-539 level risk factors (e.g. population incidence of risk-associated 540 commodities, healthcare infrastructure, age, sex), however, it 541 should be noted that the impacts these risk factors on patient 542 outcome are likely to vary significantly on a individual basis. 543 Furthermore, other genetic determinants of severity were not 544 considered³⁸. Therefore, a complete understanding of the rela-545 tive importance of MHC genotype and SARS-CoV-2 presen-546 tation capacity on patient outcome will require the integration 547 individual patient genetic and clinical data. 548

The versatility of the proposed model will be improved 549 by the consideration of additional MHC-I alleles. To reduce 550

the presence of confounding factors, EnsembleMHC was pa-

rameterized on only a subset of common MHC-I alleles that had strong existing experimental validation. While the selected

had strong existing experimental validation. While the selected
 MHC-I alleles are among some of the most common, person-

alized risk assessment will require consideration of the full

patient MHC-I genotype. The continued mass spectrometry-

based characterization of MHC-I peptide binding motifs will

help in this regard. However, due to the large potential sequence space of the MHC-I protein, extension of this model

quence space of the MHC-1 protein, extension of this modelwill likely require inference of binding motifs based on MHC

561 variant clustering.

562 Acknowledgments

⁵⁶³ We would like to thank Drs. Diego Chowell, Matthew Scotch,

Si Krishna, Shay Ferdosi, and Mr. John Vant, Mr. Ryan Boyd,

and Ms. Mollie Peters for critical feedback and discussion.

⁵⁶⁶ Finally, we would like to thank ASU Research computing for

allocating the computational resources.

568 **References**

- 569 [1] Zi Yue Zu et al. "Coronavirus disease 2019 (COVID 570 19): a perspective from China". In: *Radiology* (2020),
 571 p. 200490.
- ⁵⁷² [2] Qun Li et al. "Early transmission dynamics in Wuhan, ⁵⁷³ China, of novel coronavirus–infected pneumonia". In: ⁵⁷⁴ *New England Journal of Medicine* (2020).
- 575 [3] Yan-Rong Guo et al. "The origin, transmission and clini576 cal therapies on coronavirus disease 2019 (COVID-19)
 577 outbreak–an update on the status". In: *Military Medical*578 *Research* 7.1 (2020), pp. 1–10.
- [4] Rudragouda Channappanavar, Jincun Zhao, and Stanley
 Perlman. "T cell-mediated immune response to respiratory coronaviruses". In: *Immunologic research* 59.1-3
 (2014), pp. 118–128.
- ⁵⁸³ [5] Hsueh-Ling Janice Oh et al. "Understanding the T cell
 ⁵⁸⁴ immune response in SARS coronavirus infection". In:
 ⁵⁸⁵ *Emerging microbes & infections* 1.1 (2012), pp. 1–6.
- ⁵⁸⁶ [6] Oi-Wing Ng et al. "Memory T cell responses target-⁵⁸⁷ ing the SARS coronavirus persist up to 11 years post-⁵⁸⁸ infection". In: *Vaccine* 34.17 (2016), pp. 2008–2014.
- ⁵⁸⁹ [7] Nina Le Bert et al. "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls". In: *Nature* 584.7821 (2020), pp. 457–462.
- [8] Alba Grifoni et al. "Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals". In: *Cell* (2020).

- [9] Vasiliki Matzaraki et al. "The MHC locus and genetic 595 susceptibility to autoimmune and infectious diseases". 596 In: *Genome biology* 18.1 (2017), p. 76. 597
- [10] Marie Lin et al. "Association of HLA class I with severe acute respiratory syndrome coronavirus infection". In: BMC Medical Genetics 4.1 (2003), p. 9.
- [11] Sheng-Fan Wang et al. "Human-leukocyte antigen class 601 I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection". In: *Viral immunology* 24.5 (2011), 604 pp. 421–426. 605
- [12] Margaret HL Ng et al. "Association of human-leukocyteantigen class I (B* 0703) and class II (DRB1* 0301)
 genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome". In: *Journal of Infectious Diseases* 190.3 (2004), pp. 515– 518.
- [13] MH Ng et al. "Immunogenetics in SARS: a case-control study." In: *Hong Kong medical journal= Xianggang yi xue za zhi* 16.5 Suppl 4 (2010), p. 29.
- [14] Alicia Sanchez-Mazas. "HLA studies in the context of coronavirus outbreaks". In: *Swiss Medical Weekly* 150.1516 (2020).
- [15] Austin Nguyen et al. "Human leukocyte antigen susceptibility map for SARS-CoV-2". In: *Journal of Virology* (2020).
- [16] Weilong Zhao and Xinwei Sher. "Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes". In: *PLoS computational biology* 14.11 (2018).
- [17] Siranush Sarkizova et al. "A large peptidome dataset improves HLA class I epitope prediction across most of the human population". In: *Nature Biotechnology* 38.2 (2020), pp. 199–209.
- [18] Faviel F González-Galarza et al. "Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations". In: Nucleic acids research 43.D1 (2015), pp. D784–D788.
- Timothy J O'Donnell, Alex Rubinsteyn, and Uri Laser son. "MHCflurry 2.0: Improved Pan-Allele Prediction
 of MHC Class I-Presented Peptides by Incorporating
 Antigen Processing". In: *Cell Systems* (2020).
- [20] Vanessa Jurtz et al. "NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data". In: *The Journal* of Immunology 199.9 (2017), pp. 3360–3368.
- [21] Massimo Andreatta and Morten Nielsen. "Gapped sequence alignment using artificial neural networks: application to the MHC class I system". In: *Bioinformatics* 32.4 (2016), pp. 511–517.

- 645 [22] Michal Bassani-Sternberg et al. "Deciphering HLA-I
 646 motifs across HLA peptidomes improves neo-antigen
 647 predictions and identifies allostery regulating HLA speci-
- ficity". In: *PLoS computational biology* 13.8 (2017),
- e1005725.
- Hao Zhang, Ole Lund, and Morten Nielsen. "The PickPocket method for predicting binding specificities for
 receptors based on receptor pocket similarities: application to MHC-peptide binding". In: *Bioinformatics* 25.10
 (2009), pp. 1293–1299.
- Michael Rasmussen et al. "Pan-specific prediction of peptide–MHC class I complex stability, a correlate of T cell immunogenicity". In: *The Journal of Immunology* 197.4 (2016), pp. 1517–1524.
- [25] Sinu Paul et al. "HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity". In: *The Journal of Immunology* 191.12 (2013), pp. 5831–5839.
- [26] K Nichols. "False discovery rate procedures". In: *Statistical Parametric Mapping*. Elsevier, 2007, pp. 246–252.
- Morten Nielsen et al. "Immunoinformatics: Predicting
 Peptide–MHC Binding". In: *Annual Review of Biomedi- cal Data Science* 3 (2020).
- [28] Thomas Trolle et al. "The length distribution of class I–
 restricted T cell epitopes is determined by both peptide
 supply and MHC allele–specific binding preference".
 In: *The Journal of Immunology* 196.4 (2016), pp. 1480–
 1487.
- [29] Nicolas Rapin et al. "The MHC motif viewer: a visualization tool for MHC binding motifs". In: *Current protocols in immunology* 88.1 (2010), pp. 18–17.
- [30] Yoav Benjamini and Yosef Hochberg. "Controlling the
 false discovery rate: a practical and powerful approach
 to multiple testing". In: *Journal of the Royal statistical society: series B (Methodological)* 57.1 (1995), pp. 289–
 300.
- Elizabeth J Williamson et al. "OpenSAFELY: factors associated with COVID-19 death in 17 million patients".
 In: *Nature* (2020), pp. 1–11.
- [32] Simon de Lusignan et al. "Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study". In: *The Lancet Infectious Diseases* (2020).
- [33] Morgane Rolland et al. "Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads".
 In: *PloS one* 3.1 (2008).
- [34] Katie M Campbell et al. "Prediction of SARS-CoV-2
 epitopes across 9360 HLA class I alleles". In: *bioRxiv*(2020).

- [35] Diego Chowell et al. "Evolutionary divergence of HLA 696 class I genotype impacts efficacy of cancer immunother apy". In: *Nature medicine* 25.11 (2019), pp. 1715–1720. 698
- [36] Jatin Arora et al. "HLA heterozygote advantage against HIV-1 is driven by quantitative and qualitative differences in HLA allele-specific peptide presentation". In: *Molecular biology and evolution* 37.3 (2020), pp. 639– 650.
- [37] Nathan P Croft et al. "Most viral peptides displayed by class I MHC on infected cells are immunogenic". In: *Proceedings of the National Academy of Sciences* 116.8 (2019), pp. 3112–3117.
- [38] Yanan Cao et al. "Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations". In: *Cell discovery* 6.1 710 (2020), pp. 1–4. 711
- [39] Marek Prachar et al. "COVID-19 Vaccine Candidates: 712 Prediction and Validation of 174 SARS-CoV-2 Epitopes". In: *bioRxiv* (2020). 714
- [40] Syed Faraz Ahmed, Ahmed A Quadeer, and Matthew R
 McKay. "COVIDep: A web-based platform for real-time reporting of vaccine target recommendations for SARS CoV-2". In: *Nature reviews microbiology* 15 (2020), 718
 pp. 2141–2142. 719
- [41] Helen M Berman et al. "The protein data bank". In: *Nuccleic acids research* 28.1 (2000), pp. 235–242.
- [42] Chengxin Zhang et al. "Protein structure and sequence re-analysis of 2019-nCoV genome refutes snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1". In: *Journal of proteome research* (2020).
- [43] William Humphrey, Andrew Dalke, Klaus Schulten, et 727
 al. "VMD: visual molecular dynamics". In: *Journal of 728* molecular graphics 14.1 (1996), pp. 33–38. 728
- [44] Ensheng Dong, Hongru Du, and Lauren Gardner. "An rational interactive web-based dashboard to track COVID-19 in real time". In: *The Lancet infectious diseases* (2020). 732
- [45] Katherine S Button et al. "Power failure: why small sample size undermines the reliability of neuroscience". In: 734 *Nature Reviews Neuroscience* 14.5 (2013), pp. 365–376. 735
- [46] Andrew P Ferretti et al. "COVID-19 patients form memory CD8+ T cells that recognize a small set of shared immunodominant epitopes in SARS-CoV-2". In: (2020). 738
- [47] Annika Nelde et al. "SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition". In: *Nature immunology* (2020), pp. 1–12.
- [48] Thomas M Snyder et al. "Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels". In: *medRxiv* (2020). 744

- 745 [49] Ahmed A Quadeer, Syed Faraz Ahmed, and Matthew R
- 746 McKay. "Epitopes targeted by T cells in convalescent
- 747 COVID-19 patients". In: *bioRxiv* (2020).

A PREPRINT - DECEMBER 15, 2020

748 Methods

749 EnsembleMHC prediction workflow

EnsembleMHC component binding and processing predic-750 tion algorithms. EnsembleMHC incorporates MHC-I binding 751 and processing predictions from 7 publicly available algorithms: 752 MHCflurry-affinity-1.6.0¹⁹, MHCflurry-presentation-1.6.0¹⁹ 753 netMHC-4.0²¹, netMHCpan-4.0-EL²⁰, netMHCstabpan-1.0²⁴, 754 PickPocket-1.1²³ and, MixMHCpred-2.0.2²². These algorithms 755 were chosen based on the criteria of providing a free academic 756 license, bash command line integration, and demonstrated ac-757 curacy for predicting SARS-CoV-2 MHC-I peptides with ex-758 perimentally validated binding stability³⁹. 759

Each of the selected algorithms cover components of 760 MHC-I binding and antigen processing that roughly fall into 761 two categories: ones based primarily on MHC-I binding affin-762 ity predictions and others that model antigen presentation. 763 To this end, MHCflurry-affinity, netMHC, PickPocket, and 764 netMHCstabpan predict binding affinity based on quantitative 765 peptide binding affinity measurements. netMHCstabpan also 766 incorporates peptide-MHC stability measurements and Pick-767 Pocket performs prediction based on binding pocket structural 768 extrapolation. To model the effects of antigen presentation, 769 MixMHCpred, netMHCpan-EL, and MHCflurry-presentation 770 are trained on naturally eluted MHC-I ligands. Additionally, 771 MHCflurry-presentation incorporates an antigen processing 772 term. 773

Parameterization of EnsembleMHC using mass spectrom-774 etry data. EnsembleMHC is able to achieve high levels of 775 precision in peptide selection through the use of allele and 776 algorithm-specific binding affinity thresholds. These binding 777 affinity thresholds were identified through the parameterization 778 of each algorithm on high-quality mass spectrometry data sets¹⁷. 779 The mass spectrometry data sets used for algorithm parameteri-780 zation were collected in the largest single laboratory MS-based 781 characterization of MHC-I peptides presented by single MHC 782 783 allele cell lines. These characteristics significantly reduces the 784 number of artifacts introduced by differences in peptide isolation methods, mass spectrometry acquisition, and convolution 785 of peptides in multiallelic cell lines. An overview of the Ensem-786 bleMHC parameterization is provided in supplemental figures 787 (SI A.1). 788

Fifty-two common MHC-I alleles were selected for parameterization based on the criteria that they were characterized
in *Sarkizova et al.* data sets and that all 7 component algorithms
could perform peptide binding affinity predictions for that allele.
Each target peptide (observed in the MS data set) was paired
with 100 length-matched randomly sampled decoy peptides
(not observed in the MS data set) derived from the same source

proteins. If a protein was less than 100 amino acids in length, 796 then every potential peptide from that protein was extracted. 797

Each of the seven algorithms were independently applied 798 to each of the 52 allele data sets. For each allele data set, the 799 minimum score threshold was determined for each algorithm 800 that recovered 50% of the allele repertoire size (the total num-801 ber of target peptides observed in the MS data set for that allele). 802 Additionally, the expected accuracy of each algorithm was as-803 sessed by calculating the observed false detection rate (the 804 fraction of identified peptides that were decoy peptides) using 805 the identified algorithm and allele specific scoring threshold. 806 The parameterization process was repeated 1000 times for each 807 allele through bootstrap sampling of half of the peptides in each 808 single MHC allele data set. The final FDR and score threshold 809 for each algorithm at each allele was determined by taking 810 the median value of both quantities reported during bootstrap 811 sampling. 812

Peptide confidence assessment. Peptide confidence is assigned by calculating the $peptide^{FDR}$. This quantity is defined as the product of the empirical FDRs of each individual algorithm that detected a given peptide. The $peptide^{FDR}$ is calculated using equation 1, 817

$$peptide^{FDR} = \prod_{i=1, i \neq ND}^{N} algorithm_{i}^{FDR}$$
(1)

, where N is the number of MHC-I binding and processing algorithms, ND represents an algorithm that did not detect a given peptide, and $algorithm^{FDR}$ represents the allele specific FDR of the Nth algorithm.

The $peptide^{FDR}$ represents the joint probability that all MHC-I binding and processing algorithms that detected a particular peptide did so in error, and therefore returns a probability of false detection. Unless otherwise stated, EnsembleMHC selected peptides based on the criterion of a $peptide^{FDR} \leq$ 826 5%.

Application of EnsembleMHC to tumor cell line data 828

Tumor MHC-I peptide data sets.Ten tumor samples were829obtained from the Sarkizova et al.data sets.Tumor samples830were selected for analyis if at least 50% of the expressed MHC-831I alleles for that sample were included in the 52 MHC-I alleles832supported by EnsembleMHC.For each data set, decoy peptideswere generated in a manner identical to the method used for834algorithm parameterization on single MHC allele data.835

Tumor MHC-I peptide identification.Peptide identification836by each algorithm was based on restrictive or permissive binding affinities thresholds.These thresholds correspond to commonly used score cutoffs for the identification of strong binders836(restrictive) or all binders (permissive).These thresholds are840

A PREPRINT - DECEMBER 15, 2020

896

841 0.5% (percentile rank) or 50nM (IC50 value) for strong binders,
842 and 2% (percentile rank) or 500nM (IC50 value) for all binders.
843 Due to the lack of recommend score thresholds for MHCflurry844 presentation, the raw presentation score was converted to a

percentile score by histogramming the presentation scores pro-

⁸⁴⁶ duced by 100,000 randomly generated peptides.

Application of EnsembleMHC for the prediction of SARS-CoV-2 MHC-I peptides

SARS-CoV-2 reference sequence. MHC-I peptide predictions for the SARS-CoV-2 proteome were performed using the Wuhan-Hu-1(MN908947.3) reference sequence (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/). All
potential 8-14mer peptides (n= 67,207) were derived from the open reading frames in the reported proteome, and each peptide was evaluated by the EnsembleMHC workflow.

SARS-CoV-2 polymorphism analysis and protein structure visualizations. Polymorphism analysis of SARS-CoV-2
structural proteins were performed using 102,148 full length
protein sequences obtained from the COVIDep database⁴⁰.
Solved structures for the E (5X29) and S (6VXX) proteins
(http://www.rcsb.org/)⁴¹ and predicted structures for the M and
N proteins⁴² were visualized using VMD⁴³.

Application of EnsembleMHC to determine population SARS-CoV-2 binding capacity

The peptides identified by the EnsembleMHC workflow were
used to assess the SARS-CoV-2 population binding capacity by
weighing individual MHC allele SARS-CoV-2 binding capacities by regional expression (for a schematic representation see
SI A.6).

Population-wide MHC-I frequency estimates by country. 870 The selection of countries included in the EnsembleMHC popu-871 lation binding capacity assessment was based on several criteria 872 regarding the underlying MHC-I allele data for that country (SI 873 A.6). The MHC-I allele frequency data used in our model was 874 obtained from the Allele Frequency Net Database (AFND)¹⁸, 875 and frequencies were aggregated by country. However, the 876 currently available population-based MHC-I frequency data 877 has specific limitations and variances, which we have addressed 878 as follows: 879

Quality of MHC data within countries. We define MHC typing breadth as the diversity of identified MHC-I alleles
 within a given country, and its depth as the ability to accurately
 achieve 4-digit MHC-I genotype resolution. High variability
 was observed in both the MHC-I genotyping breadth and depth
 (SI A.6 inset). Consequently, additional filter-measures were
 introduced to capture potential sources of variance within the

880

analyzed cohort of countries. The thresholds for filtering the 888 country-wide MHC-I allele data were set based on meeting 889 two inclusion criteria: 1) MHC genotyping of at least 1000 890 individuals have been performed in that population, avoiding 891 skewing of allele frequencies due to small sample size. 2) 892 MHC-I allele frequency data for at least 51 of the 52 (95%) 893 MHC-I alleles for which the EnsembleMHC was parameterized 894 to predict, ensuring full power of the EnsembleMHC workflow. 895

Ethnic communities within countries. In instances where 897 the MHC-I allele frequencies would pertain to more than one 898 community, the reported frequencies were counted towards 899 both contributing groups. For example, the MHC-I frequency 900 data pertaining to the Chinese minority in Germany would 901 be factored into the population MHC-I frequencies for both 902 China and Germany. In doing so, this treatment resolves both 903 ancestral and demographic MHC-I allele frequencies. 904

Normalization of MHC allele frequency data. The focus of this work was to uncover potential differences in SARS-CoV-2 MHC-I peptide presentation dynamics induced by the 52 selected alleles within a population. Accordingly, the MHC-I allele frequency data was carefully processed in order to maintain important differences in the expression of selected alleles, while minimizing the effect of confounding variables. 910

The MHC-I allele frequency data for a given population was first filtered to the 52 selected alleles. These allele frequencies were then converted to the theoretical total number of copies of that allele within the population (*allele count*) following 916

$$allele\ count = allele\ _{freg} \times 2 \times n \tag{2}$$

, where $allele_{freq}$ is the observed allele frequency in a population and n is the population sample size for which that allele frequency was measured. The allele count is then normalized with respect to the total allele count of selected 52 alleles within that population using the following relationship 920

norm allele
$$count_i = \frac{allele \ count_i}{\sum\limits_{i=1}^{52} allele \ count_i}$$
 (3)

, where *i* is one of the 52 selected alleles. This normaliza-922 tion is required to overcome the potential bias towards hidden 923 alleles (alleles that are either not well characterized or not sup-924 ported by EnsembleMHC) as would be seen using alternative 925 allele frequency accounting techniques (e.g. sample-weighted 926 mean of selected allele frequencies or normalization with re-927 spect to all observed alleles within a population (SI A.22)). The 928 SARS-CoV-2 binding capacity of these hidden alleles cannot be 929 accurately determined using the EnsembleMHC workflow, and 930 therefore important potential relationships would be obscured. 931

A PREPRINT - DECEMBER 15, 2020

EnsembleMHC population score. The predicted ability of a
 given population to present SARS-CoV-2 derived peptides was
 assessed by calculating the EnsembleMHC Population (EMP)
 score. After the MHC-I allele frequency data filtering steps, 23
 countries were included in the analysis. The calculation of the
 EnsembleMHC population score is as follows

$$EMP \ score = \frac{\sum_{i=1}^{5^2} peptide_{frac} \times norm \ allele \ count_i}{N_{norm \ allele \ count \neq 0}}$$
(4)

938 , where norm allele count is the observed nor-939 malized allele count for a given allele in a population, 940 $N_{norm \ allele \ count \ \neq 0}$ is the number of the 52 select alleles 941 detected in a given population (range 51-52 alleles), and 942 $peptide_{frac}$ is the peptide fraction or the fraction of total pre-943 dicted peptides expected to be presented by that allele within 944 the total set of predicted peptides with a $peptide^{FDR} \le 5\%$.

Death rate-presentation correlation. The correlation be-945 tween the EMP score and the observed deaths per million 946 within the cohort of selected countries was calculated as a func-947 tion of time. SARS-Cov-2 data covering the time dependent 948 global evolution of the SARS-CoV-2 pandemic was obtained 949 from Johns Hopkins University Center for Systems Science 950 and Engineering⁴⁴ covering the time frame of January 22nd to 951 April 9th. The temporal variations in occurrence of community 952 spread observed in different countries were accounted for by 953 rescaling the time series data relative to when a certain mini-954 mum death threshold was met in a country. This analysis was 955 performed for minimum death thresholds of 1-100 total deaths 956 by day 0, and correlations were calculated at each day sequen-957 tially following day 0 until there were fewer than 8 countries 958 remaining at that time point. The upper-limit of 100-deaths was 959 chosen to ensure availability of death-rate data on at least 50% 960 of the countries for a minimum of 7 days starting following day 961 0. Additionally, a steep decline in average statistical power is 962 observed with day 1 death thresholds greater than 100 deaths 963 (SI A.23). 964

The time death correlation was computed using Spearman's rank correlation coefficient (two-sided). This method was chosen due to the small sample size and non-normality of the underlying data (SI A.24). The reported correlations of EMP score and deaths per million using other correlation methods can be seen in supplemental figure SI A.25.

The low statistical power for some of the obtained correlations were addressed by calculating the Positive Predictive Value (PPV) of all correlations using the following equation⁴⁵

$$PPV = \frac{1 - \beta \times R}{1 - \beta \times R + \alpha} \tag{5}$$

974 ,where $1 - \beta$ is the statistical power of a given correlation, 975 *R* is the pre-study odds, and α is the significance level. A PPV value of > 95% is analogous to a p value of < 0.05. Due to an 976 unknown pre-study odd (probability that probed effect is truly 977 non-null), R was set to 1 in the reported correlations. The pro-978 portion of reported correlations with a PPV of 95% at different 979 R values can be seen in supplemental figure SI A.17. The sig-980 nificance of partitioning high risk and low risk countries based 981 on median EMP score was determined using Mann-Whitney 982 U-test. Significance values were corrected for multiple tests 983 using the Benjamini-Hochberg procedure³⁰. 984

Sub-sampling of peptides from the Full SARS-CoV-2 pro-985 teome. 108 unique peptides, derived from the Full SARS-986 CoV-2 proteome and passing the 5% $peptide^{FDR}$ filter, were 987 randomly sampled. Then, the time series EMP score - death 988 per million correlation analysis used to generate Figure 3 was 989 applied to each sampled peptide set. The sub-sampling proce-990 dure was repeated for 1,000 iterations (SI A.18A). To quantita-991 tively describe the similarity of the distributions, the Kullback-992 Leibler divergence (KLD), a measure of divergence between 993 two probability distributions, was calculated for the correlation 994 distribution of each sub-sample iteration relative to either the 995 correlation distribution of the Full SARS-CoV-2 proteome or 996 SARS-CoV-2 structural proteins (SI A.18B). 997

Analysis of additional SARS-CoV-2 risk factors

Additional SARS-CoV-2 risk factors. Twelve poten-990 tial SARS-CoV-2 risk factors (table B.4) were selected 1000 Country-specific data for each risk factor for analysis. 1001 was obtained from the Global Health Observatory data 1002 repository provided by the World Health Organization 1003 (https://apps.who.int/gho/data/node.main). Countries were se-1004 lected for analysis based on the criteria of having reported 1005 data in the WHO data sets and inclusion in the set of 23 coun-1006 tries for which EnsembleMHC population scores were assigned 1007 (table B.4A). Data regrading the total number of noncommuni- 1008 cable disease-related deaths (Cardiovascular disease, Chronic 1009 obstructive pulmonary disease, and Diabetes mellitus) were 1010 converted to deaths per million. 1011

998

Linear models of SARS-CoV-2 mortality. For the single and 1021 combination models, individual linear models were constructed 1022 for each considered death threshold as a function of time (similar to the univariate correlation analysis). Each model consisted 1024

A PREPRINT - DECEMBER 15, 2020

of 1 (a single socioeconomic or health-related risk factor) or 2 (a combination of 1 risk factor and structural protein EMP score) dependent variables and deaths per million as the independent variable. The adjusted R^2 value and statistical significance of the model (F-test) were then extracted from each individual model and aggregated by dependent variable (**figure 4, SI A.21**).

The best performing models were determined by assessing all possible combinations of factors including structural protein EMP score. This resulted in the consideration of 4,083 different linear models. The top performing models were then selected by ranking each model by median adjusted R^2 .

1037 Code and data availability.

All data analysis and statistical tests were performed using the R Statistical Computing Environment v.3.6.0 (http://www.rproject.org). Data sets and example code are available at https://github.com/eawilson-CompBio/EnsembleMHC-Covid.git

A Supplemental figures: Total predicted MHC-I epitope load is inversely associated with population mortality from SARS-CoV-2

Eric Wilson, Gabrielle Herneise, Abhishek Singharoy, Karen S Anderson



Figure A.1: EnsembleMHC Parameterization overview



Figure A.2: EnsembleMHC prediction workflow. A, The EnsembleMHC score algorithm was parameterized using high quality mass spectrometry-detected MHC-I peptides paired with a 100-fold excess of randomly generated decoy peptides. Each bar represents the distribution of algorithm-specific false detection rates (n = 7) at that MHC allele. Each box plot is in the style of Tukey. B, a density plot of the observed FDRs for each algorithm across all alleles (n = 52). C, The correlation between individual peptide scores for each algorithm across all alleles was calculated using Pearson correlation. Warmer colors indicate a higher level of correlation while cooler colors indicate lower correlation.

A PREPRINT - DECEMBER 15, 2020



Figure A.3: The effect of different peptide FDR threshold levels. The effect of different $peptide^{FDR}$ cutoff thresholds on the results reported in figure 1 was evaluated for a range of 0.01-1. The $peptide^{FDR}$ selected for use in this study is highlighted in red.



Figure A.4: Evaluation of individual algorithms using Matthew's correlation coefficient. As an alternative to F1 score (Figure 1B), Matthew's correlation coefficient was calculated for each algorithm. Warm colors indicate higher MCC while cooler colors indicate lower MCC. The average MCC for each algorithm is represented by the margin bar plot on the right.



Figure A.5: **Prediction of viral immunogenic epitopes across ensemble-based algorithms.** A-B, The results in reported figure 1 (A-B) were compared across ensemble-based MHC-I prediction algorithms. C, The positive predictive value (precision) of the algorithms to select immunogenic MHC-I peptides was assessed across Hepatitis-C genome polyprotein (P26664), Dengue virus genome polyprotein (P14340), and the HIV-1 POL-GAG protein (P03369). All potential 8 – 14mer peptides were extracted from each protein and the resulting peptides were checked against the Immune Epitope database to identify peptides with experimentally validated immunogenicity. The result of this analysis was the generation of a data set comprised of 616 experimentally validated immunogenic peptides and 54,663 putative non-immunogenic peptides. The performance of each algorithm was then assessed by calculating the precision when selecting n number of top scoring peptides as determined by a given algorithm. Precision was calculated for each algorithm across a range of n = 25 to n = 615.

A PREPRINT - DECEMBER 15, 2020



Figure A.6: **Data processing EnsembleMHC population score calculation.** The overview of the data processing steps for the global MHC-I allele frequency data and its application in the calculation the EnsembleMHC population score with respect to the full SARS-CoV-2 proteome and SARS-CoV-2 structural proteins. (inset plots), The blue inset plot illustrates MHC-typing breadth and depth variation by showing the distribution of the total number of MHC-I alleles reported at 4-digit resolution in 86 countries. The red inset plot shows the distribution of the number of MHC-genotyped individuals in the set of countries with at least 1 reported coronavirus case. **AFND = Allele Frequency Net Database**



Figure A.7: **Contribution of each EnsembleMHC component algorithm to peptide selection for predicted SARS-CoV-2 peptides.** The UpSet plot shows the contribution of each individual component algorithm to the 658 unique SARS-CoV-2 peptides identified by EnsembleMHC. The top bar plot indicates the number of unique peptides identified by the combination of algorithms shown by the points and segments located under each bar. The bar plot on the left-hand side of the plot indicates the total number of peptides identified by each algorithm.



Figure A.8: EnsembleMHC peptide^{*FDR*} and length distributions of predicted SARS-CoV-2 MHC-I peptides. A, The distribution of the for the *peptide^{<i>FDR*} for 9,712 SARS-CoV-2 peptides that fell with the score threshold of at least one component algorithm. The red line indicates an *peptide^{<i>FDR*} level of \leq 5%. B, The length distribution of the 108 high-confidence peptides identified from SARS-CoV-2 structural proteins. C, The length distribution of the 658 high-confidence peptides identified from full SARS-CoV-2 proteome.



Figure A.9: Logo plots for the identified peptides from the SARS proteome. Logo plots were generated for MHC alleles with at least 5 peptides identified by EnsembleMHC prediction. Peptides shorter than 9 amino acids had random amino acid inserted into a non-anchor position while peptides longer than 9 amino acids had a random non-anchor position deleted. Large amino acid character height indicates a high frequency of that amino acid at that position. Amino acids are colored residue type.



Figure A.10: **Molecular origin of predicted SARS-CoV-2 structural protein MHC-I peptides.** The predicted SARS-CoV-2 structural protein MHC-I peptides were mapped onto the solved structures for the envelope and spike proteins, and the predicted structures for the nucleocapsid and membrane proteins. Red highlighted regions indicate an enrichment of predicted peptides while blue regions indicate a depletion of predicted peptides.

A PREPRINT - DECEMBER 15, 2020



Figure A.11: Impact of SARS-CoV-2 sequence polymorphism on predicted SARS-CoV-2 structural MHC-I peptides. Top 4 panels, The incidence of sequence position mutations (colored bar) and the frequency of each amino acid position in one of the 108 SARS-CoV-2 structural protein peptides (black bars) by protein were calculated for 102,148 SARS-CoV-2 sequence variants. Lower left panel, all potential mutations arising in an EnsembleMHC-predicted MHC-I peptides were evaluated for changes in binding affinity ($peptide^{FDR} > 0.05$). Lower right panel, The overall frequency of mutations impacting EnsmebleMHC-predicted peptides with light blue indicating deleterious mutations, and dark blue indicating neutral mutations.



Figure A.12: Simulated even peptide-allele distribution. The resulting SARS-CoV-2 peptide-MHC allele distribution was compared to a even distribution by means of the Kolmogorov-smirnov test. A, An even peptide-allele distribution for the full SARS-CoV-2 proteome was simulated by sampling from a discrete symmetrical distribution centered around the median number of peptides assigned to individual alleles ($\tilde{X} = 16$). B, An even peptide-allele distribution for the SARS-CoV-2 structural proteins was simulated by sampling from a discrete symmetrical distribution centered around the median number of peptides assigned to individual alleles ($\tilde{X} = 2$).



Figure A.13: **External experimental validation of the 108 high confidence SARS-Cov-2 structural protein peptides.** Experimentally validated immunogenic peptides derived from SARS-CoV-2 structural proteins were obtained from 4 independent studies (Ferretti et al⁴⁶, Nelde et al⁴⁷, and Snyder et al⁴⁸) and 1 meta-study (Quadeer et al⁴⁹). These peptides were then assessed for overlap with the 108 SARS-CoV-2 peptides identified by EnsembleMHC (*108 peptides*). **A**, The total number of peptides from the *108 peptides* set that were included for testing in each study. **B**, The summary of immunogenicity status of *108 peptides* across all studies. These summaries were split into two groups. *Total validated* indicates the total number of experimentally validate 108 peptides while *total validated (no pools)* indicates the number of experimentally validate in peptide pools. This distinction was made due to the potential of peptide pools to obscure which tested peptide is truly responsible for the observed immune response. Overall, 57% of the predicted 108 structural protein peptides were tested with 95% of tested peptides producing an immune response.



Figure A.14: Correlation of EMP score based on full SARS-CoV-2 proteome or SARS-CoV-2 structural proteins with observed deaths **per million.** A, The correlations between EnsembleMHC population score based on the full SARS-CoV-2 proteome (left) or EnsembleMHC population score based on SARS-CoV-2 structural proteins (right). B, The difference in the proportions of significant p-values and PPV between the full SARS-CoV-2 proteome (left) and SARS-CoV-2 structural proteins (right) (not corrected for multiple testing).



Figure A.15: **95% Confidence interval for the correlations between the EnsembleMHC score based on the full SARS-CoV-2 proteome and observed deaths per million**. Each individual plot shows the 95% confidence interval (grey region) for the correlations between EMP scores based on the full SARS-CoV-2 proteome and observed deaths per million (blue line) for all starting minimum death thresholds (indicated by number above plot).



Figure A.16: **95% Confidence interval for the correlations between the EnsembleMHC score based on SARS-CoV-2 structural proteins and observed deaths per million**. Each individual plot shows the 95% confidence interval (grey region) for the correlations between EMP scores based on ARS-CoV-2 structural proteins and observed deaths per million (blue line) for all starting minimum death thresholds (indicated by number above plot).



Figure A.17: Analysis of statistical power for different correlation methods. A, The statistical power of each reported correlation between EnsembleMHC population score with respect to the full SARS-CoV-2 proteome (left column) or specifically structural proteins (right column) and deaths per million were calculated at each day starting from the day a country passed a particular minimum death threshold using Pearson's correlation (top), Spearman's rho (middle), and Kendall's tau (bottom). The days from each start point were normalized, and correlations that were shown to be statistically significant are colored with a red point. The orange line indicates a power threshold of 80%. B, The line plot on the right shows the proportion of points achieving a significant PPV at different thresholds for pre-study odds (R) for the spearman correlation carried out in section 3. The blue line represents the proportion of significant correlations for EnsembleMHC score based on SARS-CoV-2 structural proteins while the red line represents the same correlations with an EnsembleMHC population score based on the full SARS-CoV-2 proteome.



Figure A.18: The effect of sub-sampling Ensemble/MHC-identified MHC-I peptides derived from the full SARS-CoV-2 proteome on EMP score - deaths per million correlation distribution. The robustness of the observed distinction between the EMP score - deaths per million correlation distributions between SARS-CoV-2 structural proteins and all SARS-CoV-2 proteins was assessed by performing sub-sampling of non-structural SARS-CoV-2 MHC-I peptides. A, 1,000 sub-sampling iterations were performed by randomly selecting 108 peptides from the full SARS-CoV-2 proteome that passed the 5% *peptide*^{FDR} filter. The correlation distribution EMP score produced by each sub-sampled set of peptides and observed deaths per million were plotted (grey lines). The correlation distribution observed for identified SARS-CoV-2 structural protein peptides (black line), all SARS-CoV-2 proteins (red line), and the median correlation distribution across all subsampling iterations (green line) were plotted for comparison. **B**, Kullback-Leibler divergence was calculated for the correlation distribution of each down sample iteration relative to either the correlation distribution of the all peptide group (AP) or the structural peptide group (SP).



Figure A.19: The effect of MHC shuffling on the correlation of EMP score and deaths per million. A, The MHC-I allele assessment of peptides that passed an individual algorithm binding affinity thresholds were shiffled prior to $peptide^{FDR}$ filtering. The red points indicate correlations with a p-value $\leq 5\%$. B, The impact of varying $peptide^{FDR}$ cutoff threshold on the shuffled MHC data set. For each $peptide^{FDR}$ cutoff threshold (x-axis), the upper bound of the shaded region indicates the 75^{th} percentile, the lower bound indicates the 25^{th} percentile, and the solid line indicates the median.



Figure A.20: Individual algorithms are unable to fully recreate the correlation with population mortality reported by EnsembleMHC. Population SARS-CoV-2 binding capacities using only single algorithms were correlated to observed deaths per million. For each algorithm, the population SARS-CoV-2 binding capacity was calculated from the resulting viral peptide-MHC allele distribution using restrictive MHC-I binding affinity cutoffs ($\leq 0.5\%$ for binding percentile scores, top 0.5% MHCflurry presentation score, and $\leq 50nm$ for PickPocket). Red points indicate a PPV $\geq 95\%$.



Figure A.21: Addition of structural protein EMP score significantly improves linear model fit to observed deaths per million. A, Linear models were constructed using either a single risk factor (yellow) or a combination of a risk factor and structural protein EMP scores (green). The x-axis indicates the number of normalized days from when a minimum death threshold was met (line color), and the y-axis indicates the observed adjusted R^2 value. B, A summary of results obtained from single feature linear models (top panel, yellow) or the combination models (bottom panel, green). The red bars indicate the median R^2 value achieved by that model and the blue bars indicate the proportion of regressions that were found to be significant (F-test ≤ 0.05).



Figure A.22: EnsembleMHC population score and deaths per million correlation using different allele frequency accounting methods. The effect of different allele frequency normalization techniques on the reported correlations between SARS-CoV-2 mortality and EMP scores based on the full SARS-CoV-2 proteome (left column) or SARS-CoV-2 structural proteins (right column). Top panel, The aggregation of allele frequencies within a particular country by taking the sample-weighted mean of reported frequencies for the 52 selected MHC-I alleles. Middle panel, Normalizing allele count with respect to all detected alleles in a given population. Bottom panel, Normalizing allele count with respect to only the 52 select alleles.



Figure A.23: **Justification of upper limit for death threshold. A**, The mean statistical power of all resulting correlations between EnsembleMHC population scores and observed deaths per million at different minimum reported death thresholds. The red line indicates a minimum death threshold of 100 deaths by day 0, the selected upper limit for analysis. **B**, The number of countries remaining at day seven using different minimum death thresholds. The cross bar indicates that there would be more than half of the considered countries remaining at day 7 when using the 100 minimum death threshold.



Figure A.24: **Justification of non-parametric correlation analysis.** The use of non-parametric correlation analysis, namely spearman's rho, is justified by the non-normality of the underlying data. EnsembleMHC population scores based on the full SARS-CoV-2 proteome and SARS-CoV-2 structural proteins were calculated for 10,000 simulated countries. Allele frequencies for simulated countries were generate by randomly sampling an observed allele frequency for each of the 52 alleles and re-normalizing to ensure the sum of allele frequencies were equal to one. **A**, The Q-Q plot for the simulated EnsembleMHC population score distribution based on the full SARS-CoV-2 proteome. **B**, The Q-Q plot for the simulated EnsembleMHC population score distribution based on SARS-CoV-2 structural proteins. **C**, The QQ plot for all reported deaths per Million. All three quantities show a considerable level of positive skewing, indicating non-normality.



population EnsembleMHC score and death rate correlation

Figure A.25: The effect of different correlation methods on the relationship between EnsembleMHC score and deaths per million. The correlation between EnsembleMHC population score with respect to all SARS-CoV-2 proteins (left column) or SARS-CoV-2 structural proteins (right columns) and deaths per million using Pearson's r (top), Spearman's rho (middle), and Kendall's tau (bottom). Correlations that were shown to be statistically significant are colored with a red point.

B tables

Figure B.1: MHC-I peptide identified by Ensemble MHC. All identified peptides with a $peptide^{FDR} \leq 0.05$ (not pictured due to size).

.

A PREPRINT - DECEMBER 15, 2020

A	В				
Countries	Minimum death threshold	Normalized day: 0.25	Normalized day: 0.5	Normalized day: 0.75	Normalized day: 1
China	5	8	15	23	30
Japan	10	7	14	20	27
South Korea	15	7	13	20	26
Taiwan	20	7	13	20	26
US	25	7	12	18	24
Hong Kong	30	7	12	17	23
France	35	7	12	17	23
Germany	40	7	12	17	23
India	45	6	11	17	22
Italy	50	6	11	17	22
Russia	55	6	11	17	22
UK	60	6	11	16	21
Iran	65	6	11	16	21
Israel	70	6	11	16	21
Croatia	75	6	11	16	21
Romania	80	6	11	15	21
Netherlands	95	6	11	15	20
Mexico	85	0	11	15	20
Ireland	90	6	11	15	20
Czechia	95	5	10	14	19
Morocco	100	5	10	14	19

Figure B.2: Description of the additional socioeconomic factors selected for analysis. A, The 23 countries for which SARS-CoV-2 population binding capacities were calculated. B, The mapping of normalized days to real days for normalized day quartiles (0.25, , 0.5, 0.75, 1) at select minimum death thresholds.

Figure B.3: EMP score correlation data. All correlation data pertaining to the correlations between EMP score and deaths per million. This includes rho estimate, 95% CI, non-normalized days, and sample size for each correlation (not pictured due to size).

A PREPRINT - DECEMBER 15, 2020

Α	В			
Countries	Factor	Abbreviation	Description	
China	% of population ≥ 65 years	65	Percentage of the population that is 65 years of age or older (2020).	
Japan	Average BMI	Avg. BMI	The age-standardized average population body mass index (2016).	
South Korea	Cardiovascular disease	CD	The deaths per million due to	
US			cardiovascular disease (2016).	
France	Chronic obstructive pulmonary disease	COPD	The deaths per million due to complications from chronic obstructive pulmonary disease (2016).	
Germany			The deaths per million due to complications from diabetes mellitus (2016).	
India	Diabetes mellitus	DM		
Italy		BP	The age-standardized percentage of the	
Russia	High blood pressure		≥ 140 or diastolic blood pressure ≥ 90 (2015).	
UK		000	The age-standardized percentage of the population with a BMI ≥ 30 (2016).	
Iran	Obesity prevalence	OBS		
Israel	Overweight prevalence	OVW	The age-standardized percentage of the population with a BMI ≥ 25 (2016).	
Croatia	Structural protein EMP		The SARS-CoV-2 structural protein	
Romania	score	SP	presentation score.	
Netherlands	% of GDP spent on health	GDP	Current health expenditure (CHE) as percentage of gross domestic product (2017).	
Mexico				
Ireland	% of total gov. expenditure on health care	GGHE	General government expenditure on health as a percentage of total (2014). The proportion of the total population that is female (2020).	
Czechia	% of population that is			
Morocco	female	SEX		

Figure B.4: Socioeconomic and health-related risk factors. A, 21 countries were selected for analysis based on the existence of data in the Global Health Observatory data repository and inclusion in the 23 country set used for EMP score analysis. B, Descriptions and abbreviations for the selected risk factors. Each factor is labeled with the year that the data was collected. In every case, the most recent data was selected for analysis.